UNSPSC 51182427: Clodronate or clodronic acid

This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula CH4Cl2O6P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0813BZ6866, chemically known as 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)benzenesulfonamide but generally known as clodronic acid, which bears US NIH Compound Identifier 2732. European Medicines Agency schedules Clodronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06693MIG.

UNSPSC 51182427 Clodronate or clodronic acid is a Commodity code representing pharmaceutical active ingredients and finished formulations sourced through multistate cooperative purchasing agreements. State and local governments procure clodronate and related bisphosphonate treatments through group purchasing organizations that aggregate demand across state agencies, counties, municipalities, and health care facilities to negotiate volume pricing and standardized supply chain terms. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which administers cooperative purchasing for participating state and local members including Oregon, represents the primary issuing vehicle for this commodity. These procurements typically require vendors to meet pharmaceutical manufacturing standards (current Good Manufacturing Practices and Drug Supply Chain Security Act compliance), maintain relationships with authorized wholesalers, and provide detailed product documentation including National Drug Codes, packaging configurations, and shelf-life specifications. Distribution occurs through established pharmaceutical wholesalers—AmerisourceBergen, Cardinal Health, and Morris & Dickson—rather than direct government purchase and inventory.

MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products effective July 1, 2026. The RFP targets manufacturers willing to supply identified pharmaceutical products at fixed or net-price structures, with evaluation weighted heavily toward price competitiveness (75 percent) and compliance with administrative and electronic data interchange requirements (15 percent combined). Vendors must carry insurance coverage including $5,000,000 commercial general liability per occurrence and $2,000,000 network security and privacy liability, commit to a 3 percent administrative fee on all purchases, and accept performance penalties for late reporting or missed onboarding timelines. The solicitation does not identify specific set-aside designations or budget ranges. Contract awards span two years for new vendors with optional extensions, aligning with MMCAP's discretion to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.